NovaBridge Biosciences
NBP
$1.52
▼
-0.07
(-4.40%)
at close
8
Visible periods
6
Metrics
Peer-ranked
Benchmarks
Price Chart
28
Health
Poor
Neutral
auto_awesome
Analytical Summary
NovaBridge Biosciences shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.
Market Cap
—
Dividend Yield
—
Revenue Growth
—
Op. Margin
—
ROIC
—
FCF / Share
—
Trailing P/E
—
Price / Book
1.8x
FCF Yield
—
Debt / Equity
—
info
Valuation on last close. End-of-day price, Sep 23, 2026.
Health Breakdown
Returns ↑
28
Financial view
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
Is the balance sheet risky?
2 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q4 FY2022 Dec 31, 2022 20-F ↗ | Q4 FY2021 Dec 31, 2021 20-F ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2019 20-F ↗ | Q4 FY2018 Dec 31, 2018 20-F ↗ |
|---|---|---|---|---|---|---|---|---|
| Debt to Equity (x) | — | — |
0.02x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-97%)
|
0.01x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-99%)
|
— | — |
-0.02x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-104%)
|
— |
| Net Debt (USD) | $-210.63M | $-68.26M | $-297.39M | $-463.24M | $-552.93M | $-729.32M | $-156.21M | — |
How resilient is the balance sheet?
2 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q4 FY2022 Dec 31, 2022 20-F ↗ | Q4 FY2021 Dec 31, 2021 20-F ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2019 20-F ↗ | Q4 FY2018 Dec 31, 2018 20-F ↗ |
|---|---|---|---|---|---|---|---|---|
| Working Capital (USD) | $190.63M | $168.24M | $271.11M | $415.87M | $652.44M | $730.66M | $111.01M | — |
| Total Equity (USD) | $230.94M | $201.16M | $242.00M | $421.90M | $715.50M | $862.40M | $-292.26M | — |
⌨️ Keyboard Shortcuts
/ Search
Esc Clear
A Annual
Q Quarterly
1-7 Jump to category
R Reset
Secondary lens
Benchmark Lens
Compare NBP against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare NBP against peers after checking the statement evidence.
Percentile Rankings
How NBP compares to all companies
Return on Common Equity (%)
-20.0%
Bottom 50%
Peers: Top 28%
Peer Comparison
NBP vs similar peers
Return on Common Equity (%)
NBP
-20.0%
#100 of 357
OTLC
94.9%
RIGL
93.8%
ETST
84.5%
Peer median: -46.90
Profit Margin (%)
NBP
—
#None of 116
TBPH
98.5%
HCM
83.3%
ZVRA
78.2%
Peer median: -0.34
Debt to Equity
NBP
—
#None of 93
BIOA
0.00x
ABUS
0.00x
SPRB
0.00x
Peer median: 0.25
Operating Margin (%)
NBP
—
#None of 112
RPRX
65.6%
PTCT
50.1%
CRMD
48.2%
Peer median: -1.35
Compare NBP with peers
Stack NBP against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced yesterday 8 years · 8 quarters